Psychedelics investment issuer Origin Therapeutics Holdings Inc. has added Canadian biotech psychedelics developer Clairvoyant Therapeutics to its portfolio.
The company’s clinical strategy is designed to enable psilocybin therapy in the European Union, UK and Canada for patients with Alcohol Use Disorder (AUD) starting in 2026.
Clairvoyant is currently advancing a Health Canada-approved Phase 2 clinical trial of psilocybin for AUD treatment. The randomized, controlled, clinical trial is set to evaluate the safety and efficacy of a 25mg synthetic psilocybin capsule versus placebo, combined with Motivational Enhancement Therapy (MET).
A total of 15 clinical trial ...
Full story available on Benzinga.com